Table 2 Registered ongoing clinical trials of TCR-T treatment for solid tumors in Clinicaltrial.org
From: Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Registration time | NO. | Status | Estimated enrollment | Target | HLA Allele | Vector | Cell sources | Tumor Type | Country |
|---|---|---|---|---|---|---|---|---|---|
Oct-22 | NCT05587543 | not yet recruiting | 24 | EBV | NA | NA | autogenous T cells | EBV positive nasopharyngeal carcinoma | China |
Oct-22 | NCT05580796 | not yet recruiting | 50 | NA | HLA-A * 02 | NA | autogenous T cells | malignant solid tumors failed to receive standard treatment | China |
Sep-22 | NCT05539833 | recruiting | 50 | NA | HLA-A*02 | NA | autogenous T cells | various solid tumors | China |
Aug-22 | NCT05483491 | recruiting | 42 | KK-LC-1 | HLA-A*01:01 | NA | autogenous T cells | gastric, breast, cervical, lung, and other KK-LC-1 positive cancers | China |
Jun-22 | NCT05438667 | recruiting | 11 | KRAS G12V or G12D | HLA-A*11:01 | NA | autogenous T cells | advanced pancreatic cancer and other solid tumors | China |
Jun-22 | NCT05417932 | recruiting | 46 | HBsAg | HLA-A *02 | NA | autogenous T cells | recurrent or metastatic HCC after standard systemic therapies | China |
May-22 | NCT05357027 | recruiting | 18 | HPV16 E6 | HLA-A*02 | NA | autogenous T cells | relapsed/refractory to standard treatment or metastatic cervical carcinoma | China |
Apr-22 | NCT05349890 | not yet recruiting | 24 | NA | NA | NA | autogenous T cells | metastatic or locoregionally advanced epithelial cancers | United States |
Apr-22 | NCT05339321 | recruiting | 36 | HBV | HLA-A *02 | NA | autogenous T cells | HBV-related HCC | China |
Jan-22 | NCT05194735 | recruiting | 180 | NA | NA | Sleeping Beauty transposon/transposase system | autogenous T cells | relapsed/refractory solid tumors | United States |
Jan-22 | NCT05195294 | not yet recruiting | 55 | HBV | NA | NA | autogenous T cells | advanced HBV-related HCC | United States |
Nov-21 | NCT05122221 | recruiting | 12 | HPV16 | NA | NA | autogenous T cells | HPV16 positive advanced cervical, anal, or head and neck cancers | China |
Nov-21 | NCT05124743 | recruiting | 2000 | NA | NA | NA | autogenous T cells | various solid tumors | United States |
Sep-21 | NCT05035407 | recruiting | 100 | KK-LC-1 | HLA-*A01:01 | NA | autogenous T cells | gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers | United States |
Mar-21 | NCT04809766 | recruiting | 15 | Mesothelin | HLA-A*02:01 | NA | autogenous T cells | metastatic pancreatic ductal adenocarcinoma | United States |
Feb-21 | NCT04745403 | recruiting | 10 | HBV | HLA-A*02:01 or HLA-A*24:02 | NA | autogenous T cells | Hepatitis B Virus (HBV)-related HCC | China |
Jan-21 | NCT04729543 | recruiting | 20 | MAGE-C2 | HLA-A*02 | NA | autogenous T cells | MAGE-C2-positive melanoma and head and neck cancer | Netherlands |
Dec-20 | NCT04677088 | active, not recruiting | 7 | HBV | NA | NA | autogenous T cells | HCC in post liver transplantation | China |
Nov-20 | NCT04639245 | suspended | 18 | MAGE-A1 | HLA-A*02:01 | NA | autogenous T cells | metastatic triple negative breast cancer, urothelial cancer, or non-small cell lung cancer | United States |
Aug-20 | NCT04509726 | recruiting | 20 | LMBP2 | NA | NA | autogenous T cells | metastatic/refractory nasopharyngeal carcinoma | China |
Mar-20 | NCT04318964 | recruiting | 12 | NY-ESO-1 | HLA-A * 02:01 | NA | autogenous T cells | sarcoma | China |
May-19 | NCT03941626 | recruiting | 50 | EGFRvIII/DR5/NY-ESO-1/Mesothelin | NA | NA | autogenous T cells | solid malignancies | China |
May-19 | NCT03970382 | suspended | 21 | NA | NA | NA | autogenous T cells | locally advanced or metastatic solid tumors | United States |
Mar-19 | NCT03891706 | recruiting | 30 | NA | NA | NA | NA | advanced solid tumors | China |
Dec-18 | NCT03778814 | recruiting | 30 | KK-LC-1 | NA | NA | autogenous T cells | lung cancer and other solid tumors | China |
Nov-18 | NCT03747484 | recruiting | 16 | MCPyV | HLA-A*02 | NA | autogenous T cells | metastatic or unresectable Merkel cell cancer | United States |
Oct-18 | NCT03691376 | active, not recruiting | 4 | NY-ESO-1 | HLA- A*02:01 | NA | autogenous T cells | recurrent or treatment refractory ovarian, fallopian tube or primary peritoneal cancer | United States |
Mar-18 | NCT03462316 | recruiting | 20 | NY-ESO-1 | HLA-A*02:01 | NA | autogenous T cells | bone and soft tissue sarcoma | China |
Aug-16 | NCT02858310 | recruiting | 180 | HPV-16 E7 | HLA-A*02 | NA | autogenous T cells | metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers | United States |